164 related articles for article (PubMed ID: 19180100)
1. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
Nat Rev Drug Discov; 2009 Feb; 8(2):99. PubMed ID: 19180100
[No Abstract] [Full Text] [Related]
2. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
3. Rosiglitazone and the FDA.
Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
[No Abstract] [Full Text] [Related]
4. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
Lipska KJ; Krumholz HM
JAMA; 2017 Mar; 317(10):1017-1018. PubMed ID: 28125758
[No Abstract] [Full Text] [Related]
5. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
[TBL] [Abstract][Full Text] [Related]
6. Reflections on using non-inferiority randomised placebo controlled trials in assessing cardiovascular safety of new agents for treatment of type 2 diabetes.
Campbell-Scherer D
Evid Based Med; 2017 Apr; 22(2):54-56. PubMed ID: 28274954
[TBL] [Abstract][Full Text] [Related]
7. The Yin and the Yang of CV risks in patients with diabetes.
Dangi-Garimella S
Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
[No Abstract] [Full Text] [Related]
8. FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on.
Mullard A
Nat Rev Drug Discov; 2018 Dec; 17(12):850-851. PubMed ID: 30443037
[No Abstract] [Full Text] [Related]
9. [Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Eckert S; Erdmann E; Lundershausen R; Forst T; Scherbaum WA; Schnell O; Standl E; Schumm-Draeger PM; Tschöpe D; Walter H; Weber M
Dtsch Med Wochenschr; 2007 Dec; 132(49):2650-3. PubMed ID: 18050033
[No Abstract] [Full Text] [Related]
10. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
[No Abstract] [Full Text] [Related]
11. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development.
Hwang TJ; Franklin JM; Kesselheim AS
Clin Pharmacol Ther; 2017 Aug; 102(2):290-296. PubMed ID: 28390139
[TBL] [Abstract][Full Text] [Related]
12. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes.
Matthews DR; Tsapas A
Diab Vasc Dis Res; 2008 Sep; 5(3):216-8. PubMed ID: 18777497
[No Abstract] [Full Text] [Related]
13. ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients.
Karalliedde J; Gnudi L
Nephrol Dial Transplant; 2008 Jun; 23(6):1796-8. PubMed ID: 18403430
[No Abstract] [Full Text] [Related]
14. Model-based benefit-risk assessment: can Archimedes help?
Krishna R
Clin Pharmacol Ther; 2009 Mar; 85(3):239-40. PubMed ID: 19223878
[TBL] [Abstract][Full Text] [Related]
15. [Hypoglycemia and cardiovascular risk].
Avogaro A
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
Boyle P
South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
[No Abstract] [Full Text] [Related]
17. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
Wareham NJ; Pfister R
Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
[TBL] [Abstract][Full Text] [Related]
18. Tight blood glucose control.
Frank SJ
Geriatrics; 2008 Oct; 63(10):3; author reply 3. PubMed ID: 18828649
[No Abstract] [Full Text] [Related]
19. Tight blood glucose control.
Bloomgarden ZT
Geriatrics; 2008 Oct; 63(10):3; author reply 3. PubMed ID: 18828648
[No Abstract] [Full Text] [Related]
20. Diabetes. Paradoxical effects of tightly controlled blood sugar.
Taubes G
Science; 2008 Oct; 322(5900):365-7. PubMed ID: 18927369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
